Segall Bryant & Hamill LLC Buys 140,709 Shares of Celldex Therapeutics, Inc. $CLDX

Segall Bryant & Hamill LLC boosted its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 36.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 528,597 shares of the biopharmaceutical company’s stock after buying an additional 140,709 shares during the period. Segall Bryant & Hamill LLC owned approximately 0.80% of Celldex Therapeutics worth $13,675,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in CLDX. Commodore Capital LP lifted its holdings in shares of Celldex Therapeutics by 7.8% in the 2nd quarter. Commodore Capital LP now owns 3,450,000 shares of the biopharmaceutical company’s stock worth $70,208,000 after purchasing an additional 250,000 shares in the last quarter. Bellevue Group AG boosted its holdings in shares of Celldex Therapeutics by 7.7% in the 2nd quarter. Bellevue Group AG now owns 3,307,569 shares of the biopharmaceutical company’s stock worth $67,309,000 after buying an additional 235,954 shares during the last quarter. Vestal Point Capital LP boosted its stake in Celldex Therapeutics by 781.0% in the second quarter. Vestal Point Capital LP now owns 1,750,000 shares of the biopharmaceutical company’s stock valued at $35,612,000 after acquiring an additional 1,551,354 shares during the last quarter. Geode Capital Management LLC grew its holdings in Celldex Therapeutics by 5.2% during the second quarter. Geode Capital Management LLC now owns 1,672,980 shares of the biopharmaceutical company’s stock valued at $34,050,000 after purchasing an additional 83,174 shares during the period. Finally, Fisher Asset Management LLC grew its stake in shares of Celldex Therapeutics by 12.8% during the 3rd quarter. Fisher Asset Management LLC now owns 927,157 shares of the biopharmaceutical company’s stock worth $23,986,000 after acquiring an additional 104,949 shares during the period.

Celldex Therapeutics Trading Down 3.5%

Shares of CLDX opened at $28.94 on Wednesday. Celldex Therapeutics, Inc. has a 1-year low of $14.40 and a 1-year high of $31.31. The firm has a fifty day simple moving average of $25.80 and a two-hundred day simple moving average of $25.58. The firm has a market cap of $1.93 billion, a PE ratio of -7.44 and a beta of 1.17.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($1.00) by ($0.22). The company had revenue of $0.12 million during the quarter, compared to analysts’ expectations of $1.53 million. Celldex Therapeutics had a negative return on equity of 41.67% and a negative net margin of 3,446.88%. As a group, research analysts forecast that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on CLDX. Barclays increased their price objective on Celldex Therapeutics from $21.00 to $24.00 and gave the stock an “underweight” rating in a report on Wednesday, December 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Wednesday, January 21st. Stifel Nicolaus reaffirmed a “buy” rating and set a $68.00 target price (up from $58.00) on shares of Celldex Therapeutics in a report on Thursday, February 26th. Finally, The Goldman Sachs Group lifted their price target on Celldex Therapeutics from $30.00 to $34.00 and gave the stock a “neutral” rating in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $44.50.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.